Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Ludi and I will be your conference operator today. At this time, I would like to welcome everyone to the CurioFarm Therapeutics second quarter 2025 financial results conference call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the conference over to Brendan Strong, Senior Vice President, Investor Relations and Corporate Communications. Please go ahead. Good morning. Thank you for joining us on today's conference call to discuss CarioFarm's second quarter 2025 financial results and recent company progress. We issued a press release this morning detailing our financial results for the second quarter of 2025. This release, along with a slide presentation that we will reference during our call today, are available on our website. For today's call, as seen on slide two, I'm joined by Richard, Reshma, Sohanya, and Lori, who will provide an update on our results for the second quarter of 2025 and discuss recent clinical developments. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 as outlined on slide three. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factor section of our most recent Form 10-Q or 10-K on file with the SEC and in other filings that we may make with the SEC in the future. Any forward-looking statements represent our views as of today only. While we may elect to update these forward-looking statements at some point...